JP6864008B2 - 抗リン脂質抗体症候群に関連するループス抗凝固因子(la)を特定するための方法およびキット - Google Patents
抗リン脂質抗体症候群に関連するループス抗凝固因子(la)を特定するための方法およびキット Download PDFInfo
- Publication number
- JP6864008B2 JP6864008B2 JP2018553480A JP2018553480A JP6864008B2 JP 6864008 B2 JP6864008 B2 JP 6864008B2 JP 2018553480 A JP2018553480 A JP 2018553480A JP 2018553480 A JP2018553480 A JP 2018553480A JP 6864008 B2 JP6864008 B2 JP 6864008B2
- Authority
- JP
- Japan
- Prior art keywords
- phospholipid
- coagulation
- plasma
- patient
- aptt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003146 anticoagulant agent Substances 0.000 title claims description 56
- 229940127219 anticoagulant drug Drugs 0.000 title claims description 55
- 238000000034 method Methods 0.000 title claims description 49
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 title claims description 31
- 206010025135 lupus erythematosus Diseases 0.000 title claims description 24
- 210000002381 plasma Anatomy 0.000 claims description 97
- 150000003904 phospholipids Chemical class 0.000 claims description 90
- 230000015271 coagulation Effects 0.000 claims description 76
- 238000005345 coagulation Methods 0.000 claims description 76
- 238000012360 testing method Methods 0.000 claims description 65
- 230000001419 dependent effect Effects 0.000 claims description 35
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 claims description 32
- 239000003153 chemical reaction reagent Substances 0.000 claims description 30
- 239000003112 inhibitor Substances 0.000 claims description 26
- 229940122388 Thrombin inhibitor Drugs 0.000 claims description 25
- 239000003868 thrombin inhibitor Substances 0.000 claims description 24
- 238000007820 coagulation assay Methods 0.000 claims description 23
- 108010007267 Hirudins Proteins 0.000 claims description 22
- 102000007625 Hirudins Human genes 0.000 claims description 22
- 229940006607 hirudin Drugs 0.000 claims description 22
- 229960003856 argatroban Drugs 0.000 claims description 19
- KXNPVXPOPUZYGB-XYVMCAHJSA-N argatroban Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2 KXNPVXPOPUZYGB-XYVMCAHJSA-N 0.000 claims description 19
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 18
- 230000035945 sensitivity Effects 0.000 claims description 15
- 229940123583 Factor Xa inhibitor Drugs 0.000 claims description 13
- 230000007812 deficiency Effects 0.000 claims description 13
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 claims description 12
- 238000006386 neutralization reaction Methods 0.000 claims description 12
- 208000007536 Thrombosis Diseases 0.000 claims description 10
- 239000003130 blood coagulation factor inhibitor Substances 0.000 claims description 10
- 239000000377 silicon dioxide Substances 0.000 claims description 9
- 210000004623 platelet-rich plasma Anatomy 0.000 claims description 7
- 239000005995 Aluminium silicate Substances 0.000 claims description 6
- 108010094028 Prothrombin Proteins 0.000 claims description 6
- 102100027378 Prothrombin Human genes 0.000 claims description 6
- 235000012211 aluminium silicate Nutrition 0.000 claims description 6
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims description 6
- 229940039716 prothrombin Drugs 0.000 claims description 6
- 229960001148 rivaroxaban Drugs 0.000 claims description 6
- KGFYHTZWPPHNLQ-AWEZNQCLSA-N rivaroxaban Chemical compound S1C(Cl)=CC=C1C(=O)NC[C@@H]1OC(=O)N(C=2C=CC(=CC=2)N2C(COCC2)=O)C1 KGFYHTZWPPHNLQ-AWEZNQCLSA-N 0.000 claims description 6
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 claims description 5
- QNZCBYKSOIHPEH-UHFFFAOYSA-N Apixaban Chemical compound C1=CC(OC)=CC=C1N1C(C(=O)N(CC2)C=3C=CC(=CC=3)N3C(CCCC3)=O)=C2C(C(N)=O)=N1 QNZCBYKSOIHPEH-UHFFFAOYSA-N 0.000 claims description 5
- HGVDHZBSSITLCT-JLJPHGGASA-N Edoxaban Chemical compound N([C@H]1CC[C@@H](C[C@H]1NC(=O)C=1SC=2CN(C)CCC=2N=1)C(=O)N(C)C)C(=O)C(=O)NC1=CC=C(Cl)C=N1 HGVDHZBSSITLCT-JLJPHGGASA-N 0.000 claims description 5
- 108090000190 Thrombin Proteins 0.000 claims description 5
- 239000002506 anticoagulant protein Substances 0.000 claims description 5
- 229960003886 apixaban Drugs 0.000 claims description 5
- 229950011103 betrixaban Drugs 0.000 claims description 5
- XHOLNRLADUSQLD-UHFFFAOYSA-N betrixaban Chemical compound C=1C=C(Cl)C=NC=1NC(=O)C1=CC(OC)=CC=C1NC(=O)C1=CC=C(C(=N)N(C)C)C=C1 XHOLNRLADUSQLD-UHFFFAOYSA-N 0.000 claims description 5
- 230000023555 blood coagulation Effects 0.000 claims description 5
- 229960003850 dabigatran Drugs 0.000 claims description 5
- YBSJFWOBGCMAKL-UHFFFAOYSA-N dabigatran Chemical compound N=1C2=CC(C(=O)N(CCC(O)=O)C=3N=CC=CC=3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 YBSJFWOBGCMAKL-UHFFFAOYSA-N 0.000 claims description 5
- 229960000622 edoxaban Drugs 0.000 claims description 5
- 229960004408 lepirudin Drugs 0.000 claims description 5
- OTQCKZUSUGYWBD-BRHMIFOHSA-N lepirudin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)[C@@H](C)O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 OTQCKZUSUGYWBD-BRHMIFOHSA-N 0.000 claims description 5
- DKWNMCUOEDMMIN-PKOBYXMFSA-N melagatran Chemical compound C1=CC(C(=N)N)=CC=C1CNC(=O)[C@H]1N(C(=O)[C@H](NCC(O)=O)C2CCCCC2)CC1 DKWNMCUOEDMMIN-PKOBYXMFSA-N 0.000 claims description 5
- 229960002137 melagatran Drugs 0.000 claims description 5
- 108010000499 Thromboplastin Proteins 0.000 claims description 4
- 102000002262 Thromboplastin Human genes 0.000 claims description 4
- OIRCOABEOLEUMC-GEJPAHFPSA-N bivalirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OIRCOABEOLEUMC-GEJPAHFPSA-N 0.000 claims description 4
- 229960001500 bivalirudin Drugs 0.000 claims description 4
- 108010055460 bivalirudin Proteins 0.000 claims description 4
- 230000036961 partial effect Effects 0.000 claims description 4
- 229960004072 thrombin Drugs 0.000 claims description 3
- 239000003998 snake venom Substances 0.000 claims description 2
- 238000007865 diluting Methods 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 1
- 238000003556 assay Methods 0.000 description 63
- 239000000523 sample Substances 0.000 description 39
- 230000000694 effects Effects 0.000 description 26
- 238000012790 confirmation Methods 0.000 description 16
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 15
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 15
- 239000003114 blood coagulation factor Substances 0.000 description 15
- 238000001514 detection method Methods 0.000 description 13
- 238000003745 diagnosis Methods 0.000 description 12
- 238000010606 normalization Methods 0.000 description 11
- 238000007711 solidification Methods 0.000 description 9
- 230000008023 solidification Effects 0.000 description 9
- 206010067787 Coagulation factor deficiency Diseases 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 208000014763 coagulation protein disease Diseases 0.000 description 7
- 230000002159 abnormal effect Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 239000013610 patient sample Substances 0.000 description 5
- 108010074860 Factor Xa Proteins 0.000 description 4
- 208000015294 blood coagulation disease Diseases 0.000 description 4
- 238000004590 computer program Methods 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 201000003542 Factor VIII deficiency Diseases 0.000 description 3
- 201000007176 Factor XII Deficiency Diseases 0.000 description 3
- 208000009292 Hemophilia A Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 201000007382 factor V deficiency Diseases 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 206010016077 Factor IX deficiency Diseases 0.000 description 2
- 206010020608 Hypercoagulation Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 208000027276 Von Willebrand disease Diseases 0.000 description 2
- WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Natural products C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 239000012470 diluted sample Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000440 effect on coagulation Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 208000005376 factor X deficiency Diseases 0.000 description 2
- 201000007219 factor XI deficiency Diseases 0.000 description 2
- 229940003169 factor viii / von willebrand factor Drugs 0.000 description 2
- 208000009429 hemophilia B Diseases 0.000 description 2
- 230000003027 hypercoagulation Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000007423 screening assay Methods 0.000 description 2
- 230000001026 thromboplastic effect Effects 0.000 description 2
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 101710163968 Antistasin Proteins 0.000 description 1
- 206010003178 Arterial thrombosis Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 229940123900 Direct thrombin inhibitor Drugs 0.000 description 1
- 108010014172 Factor V Proteins 0.000 description 1
- 208000008899 Habitual abortion Diseases 0.000 description 1
- 208000024659 Hemostatic disease Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- -1 anionic phospholipids Chemical class 0.000 description 1
- 229940127090 anticoagulant agent Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 201000007386 factor VII deficiency Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000002607 heparin antagonist Substances 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 230000000803 paradoxical effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 208000034213 recurrent susceptibility to 1 pregnancy loss Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 201000005665 thrombophilia Diseases 0.000 description 1
- 208000012908 vascular hemostatic disease Diseases 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Description
Rs:(スクリーン凝固時間(試験試料))/(スクリーン凝固時間(NPP))
Rc:(コンファーム凝固時間(試験試料))/(コンファーム凝固時間(NPP))
R:(スクリーン凝固時間(試験試料))/(コンファーム凝固時間(試験試料))
NR:Rs/Rc
[0060] d−フェニルアラニル−1−プロリル−1−アルギニンクロロメチルケトン(PPACK)は、トロンビンの触媒部位に可逆的に結合する合成ペプチドである。図1〜3を参照すると、SCTアッセイにおけるPPACKの使用が示され、血漿試験試料は、試験中、LA陰性血漿試料プールと1:1の比で混合された(すなわち、混合試験設定)。混合試験により、正常な血漿中に存在する凝固因子が、血液凝固異常を有すると疑われる試験血漿に加えられる。凝血異常(凝固時間の延長)が補正されると、試験血漿は凝固因子を欠き、LAを有さない。
Claims (28)
- 患者の抗リン脂質抗体症候群に関連するループス抗凝固因子を検出する方法であって、
a)前記患者由来の血漿試料に複数の凝血阻害剤および第1濃度のリン脂質を添加した後に測定されるリン脂質依存性凝固アッセイにおいて、前記患者由来の血漿試料の第1の凝固時間を検出するステップ;
b)前記患者由来の血漿試料にステップa)の前記複数の凝血阻害剤およびステップa)の前記第1濃度のリン脂質より高い第2濃度のリン脂質を添加した後に測定されるリン脂質凝固アッセイにおいて、前記血漿試料の第2の凝固時間を検出するステップ;
c)ステップa)の患者血漿の凝固時間の、ステップb)の患者血漿中の凝固時間に対する患者比を決定し、健常な対象から確定した適切な参照値に正規化されたカットオフ比に対し、前記患者比を比較するステップ;を含み、ステップc)で決定された前記患者比が前記カットオフ比よりも大きいことは、前記患者由来の血漿試料中のループス抗凝固因子の存在を示す、方法。 - ステップa)のリン脂質依存性凝固アッセイおよびステップb)のリン脂質依存性凝固アッセイのそれぞれが、乏血小板血漿をさらに含む、請求項1に記載の方法。
- 前記リン脂質依存性凝固アッセイが、活性化部分トロンボプラスチン時間(APTT)を含む、請求項1に記載の方法。
- 前記リン脂質依存性凝固アッセイが、希釈ラッセル蛇毒時間(dRVVT)、APTTベース血小板中和法(PNP)、APTTベース六方晶相リン脂質中和試験、APTTベースカオリン凝固時間(KCT)、APTTベースシリカ凝固時間(SCT)および希釈プロトロンビン時間(dPT)からなる群から選択される、請求項1に記載の方法。
- 前記複数の凝血阻害剤が、少なくとも1種のトロンビン阻害剤を含む、請求項1に記載の方法。
- 前記少なくとも1種のトロンビン阻害剤は、d−フェニルアラニル−1−プロリル−1−アルギニンクロロメチルケトン(PPACK)、I−2581、ヒルジン、ヒルジン誘導体、レピルジン、デシルジン、ヒルジン類似体、ビバリルジン、アルガトロバン、メラガトラン、ダビガトラン、およびこれらの組み合わせからなる群から選択される、請求項5に記載の方法。
- 前記複数の凝血阻害剤が、リバーロキサバン、アピキサバン、エドキサバン、ベトリキサバン、アンチスタシン、ダニ抗凝固タンパク質(TAP)、およびこれらの組み合わせからなる群から選択される少なくとも1種の第Xa因子阻害剤を含む、請求項1に記載の方法。
- 前記患者血漿試料を正常なプール血漿で希釈するステップをさらに含む、請求項2に記載の方法。
- 前記患者血漿試料を、正常なプール血漿と1:1で希釈するステップをさらに含む、請求項2に記載の方法。
- 前記患者血漿試料を、正常なプール血漿と1:2、1:3または1:4で希釈するステップをさらに含む、請求項2に記載の方法。
- 前記第1濃度のリン脂質が、0.002(g/l)〜0.2(g/l)の範囲を含む、請求項1に記載の方法。
- 前記第2濃度のリン脂質が、0.2(g/l)〜5.0(g/l)の範囲を含む、請求項1に記載の方法。
- 患者の抗リン脂質抗体症候群に関連するループス抗凝固因子を検出するキットであって、
a)第1濃度のリン脂質を含むリン脂質依存性凝固試薬;
b)複数の凝血阻害剤;および
c)a)のリン脂質の第1濃度より高いリン脂質の第2濃度を含むリン脂質依存性凝固試薬、を含むキット。 - 正常なプール血漿をさらに含む、請求項13に記載のキット。
- 前記リン脂質依存性凝固試薬がAPTTを含む、請求項13に記載のキット。
- 前記リン脂質依存性凝固試薬が、dRVVT、APTTベース血小板中和法(PNP)、APTTベース六方晶相リン脂質中和試験、APTTベースカオリン凝固時間(KCT)、APTTベースシリカ凝固時間(SCT)および希釈プロトロンビン時間(dPT)からなる群から選択される、請求項13に記載のキット。
- 前記複数の凝血阻害剤が、少なくとも1種のトロンビン阻害剤を含む、請求項13に記載のキット。
- 前記少なくとも1種のトロンビン阻害剤が、d−フェニルアラニル−1−プロリル−1−アルギニンクロロメチルケトン(PPACK)、I−2581、ヒルジン、ヒルジン誘導体、レピルジン、デシルジン、ヒルジン類似体、ビバリルジン、アルガトロバン、メラガトラン、ダビガトラン、およびこれらの組み合わせからなる群から選択される、請求項17に記載のキット。
- 前記複数の凝血阻害剤が、リバーロキサバン、アピキサバン、エドキサバン、ベトリキサバン、アンチスタシン、ダニ抗凝固タンパク質(TAP)、およびこれらの組み合わせからなる群から選択される少なくとも1種の第Xa因子阻害剤を含む、請求項13に記載のキット。
- 前記複数の凝血阻害剤および前記第1濃度のリン脂質を含む前記リン脂質依存性凝固試薬が、同じ容器中に収容される、請求項13に記載のキット。
- 前記複数の凝血阻害剤および前記第2濃度のリン脂質を含む前記リン脂質依存性凝固試薬が、同じ容器中に収容される、請求項13に記載のキット。
- 前記正常なプール血漿が、前記複数の凝血阻害剤と同じ容器中に収容される、請求項14に記載のキット。
- 前記複数の凝血阻害剤が、トロンビン阻害剤および非トロンビン凝血阻害剤の組み合わせである、請求項1に記載の方法。
- 前記非トロンビン凝血阻害剤が第Xa因子阻害剤を含む、請求項23に記載の方法。
- 前記複数の凝血阻害剤および乏血小板血漿混合物が、血漿中の因子欠乏または凝血阻害剤の存在により引き起こされる干渉を減らし、ループス抗凝固因子の検出方法の特異性および感度を高める、請求項2に記載の方法。
- 前記カットオフ比が、1.00〜1.20のNRの比である、請求項1に記載の方法。
- 前記第1濃度のリン脂質が、0.002(g/l)〜0.2(g/l)の範囲を含む、請求項13に記載のキット。
- 前記第2濃度のリン脂質が、0.2(g/l)〜5.0(g/l)の範囲を含む、請求項13に記載のキット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662327028P | 2016-04-25 | 2016-04-25 | |
US62/327,028 | 2016-04-25 | ||
PCT/US2017/028286 WO2017189294A1 (en) | 2016-04-25 | 2017-04-19 | Method and kit for identifying lupus anticoagulant (la) associated with antiphospholipid syndrome |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019515259A JP2019515259A (ja) | 2019-06-06 |
JP6864008B2 true JP6864008B2 (ja) | 2021-04-21 |
Family
ID=58708002
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018553480A Active JP6864008B2 (ja) | 2016-04-25 | 2017-04-19 | 抗リン脂質抗体症候群に関連するループス抗凝固因子(la)を特定するための方法およびキット |
Country Status (7)
Country | Link |
---|---|
US (2) | US10935560B2 (ja) |
EP (1) | EP3449261B1 (ja) |
JP (1) | JP6864008B2 (ja) |
CN (1) | CN109073662A (ja) |
AU (1) | AU2017257267B2 (ja) |
CA (1) | CA3020980C (ja) |
WO (1) | WO2017189294A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7328251B2 (ja) * | 2018-11-15 | 2023-08-16 | 積水メディカル株式会社 | 分析方法、分析装置及び分析プログラム |
US11319122B2 (en) * | 2019-01-04 | 2022-05-03 | Instrumentation Laboratory Company | Container stopper for high pierce count applications |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69919702T2 (de) * | 1998-06-08 | 2005-09-15 | The University Of Vermont And State Agricultural College | Verfahren zur Bestimmung der Blutgerinnung in Plasma |
US20040091952A1 (en) * | 2002-07-25 | 2004-05-13 | Sysmex Corporation | Reagent kit for detecting lupus anticoagulant |
JP4262550B2 (ja) * | 2002-07-25 | 2009-05-13 | シスメックス株式会社 | ループスアンチコアグラント検出試薬キット |
DE602004016906D1 (de) * | 2003-03-28 | 2008-11-20 | Sysmex Corp | Reagenz zum Nachweis von anti-Phospholipid Antikörper |
US7932021B2 (en) * | 2005-07-28 | 2011-04-26 | American Diagnostica, Inc. | Lupus anticoagulant testing |
ES2528592T3 (es) | 2008-06-18 | 2015-02-10 | Sekisui Medical Co., Ltd. | Método para determinar la causa de la prolongación del tiempo de coagulación sanguínea |
SG10201908570RA (en) * | 2010-03-31 | 2019-11-28 | Hospital For Sick Children | Use of remote ischemic conditioning to improve outcome after myocardial infarction |
EP2655399B1 (en) * | 2010-12-21 | 2017-09-27 | The Medicines Company (Leipzig) GmbH | Trypsin-like serine protease inhibitors, their preparation and use as selective inhibitors of the clotting factors iia and xa |
JP5903215B2 (ja) * | 2011-02-28 | 2016-04-13 | シスメックス株式会社 | ループスアンチコアグラント検出用試薬キット及びループスアンチコアグラントの存否を判定する方法 |
JP5640189B2 (ja) | 2011-06-17 | 2014-12-17 | 学校法人東日本学園 | ループスアンチコアグラント検出用血液凝固時間の測定方法 |
JP5911345B2 (ja) | 2012-03-27 | 2016-04-27 | シスメックス株式会社 | 凝固時間測定用試薬、凝固時間測定用試薬キットおよび凝固時間の測定方法 |
-
2017
- 2017-04-19 JP JP2018553480A patent/JP6864008B2/ja active Active
- 2017-04-19 AU AU2017257267A patent/AU2017257267B2/en active Active
- 2017-04-19 WO PCT/US2017/028286 patent/WO2017189294A1/en active Application Filing
- 2017-04-19 CN CN201780025859.XA patent/CN109073662A/zh active Pending
- 2017-04-19 CA CA3020980A patent/CA3020980C/en active Active
- 2017-04-19 EP EP17723549.6A patent/EP3449261B1/en active Active
- 2017-04-19 US US15/491,152 patent/US10935560B2/en active Active
-
2021
- 2021-01-15 US US17/150,454 patent/US20210132088A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3449261B1 (en) | 2023-08-30 |
AU2017257267B2 (en) | 2020-05-14 |
CA3020980A1 (en) | 2017-11-02 |
AU2017257267A1 (en) | 2018-11-01 |
WO2017189294A1 (en) | 2017-11-02 |
CA3020980C (en) | 2023-10-24 |
US20210132088A1 (en) | 2021-05-06 |
CN109073662A (zh) | 2018-12-21 |
JP2019515259A (ja) | 2019-06-06 |
EP3449261A1 (en) | 2019-03-06 |
US20170307641A1 (en) | 2017-10-26 |
US10935560B2 (en) | 2021-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Miesbach et al. | Comparison of the fibrinogen Clauss assay and the fibrinogen PT derived method in patients with dysfibrinogenemia | |
Quiroga et al. | Template bleeding time and PFA‐100® have low sensitivity to screen patients with hereditary mucocutaneous hemorrhages: comparative study in 148 patients | |
US20190353674A1 (en) | Method for determining cause of the prolongation of blood coagulation time | |
Panteghini | Present issues in the determination of troponins and other markers of cardiac damage | |
EP2235542B1 (en) | Diagnostic in vitro method for assessing von willebrand disease and increased bleeding risk associated with von willebrand disease and acquired or congenital disorders of platelet function | |
Kumano et al. | Verification of the guidelines for lupus anticoagulant detection: usefulness of index for circulating anticoagulant in APTT mixing test | |
Rimsans et al. | Overview and practical application of coagulation assays in managing anticoagulation with direct oral anticoagulants (DOACs) | |
US20210132088A1 (en) | Lupus anticoagulant (la) mixing method and kit with reduced factor deficiency effect and reduced inhibitor interference for identifying la associated with antiphospholipid syndrome | |
Dumoulin et al. | Investigation of sensitivity for coagulation factor deficiency in APTT and PT: how to perform it? | |
JP6028314B2 (ja) | ループスアンチコアグラントの検出方法 | |
Kumano et al. | New formulas for mixing test to discriminate between lupus anticoagulant and acquired hemophilia A | |
JP6625730B2 (ja) | Fviiiインヒビター検出のための新規な自動化スクリーニング法の開発 | |
KR20200118428A (ko) | 활성탄을 사용하여 지혈 장애를 진단하는 방법 | |
Chikasawa et al. | Comprehensive comparison of global coagulation assays to differentiate lupus anticoagulant from acquired hemophilia A in patients with prolonged APTT | |
Ohsaka et al. | Automated mixing studies and pattern recognition for the laboratory diagnosis of a prolonged activated partial thromboplastin time using an automated coagulation analyzer | |
JP4414530B2 (ja) | 凝固系における欠損箇所を見出す方法 | |
EP2073015A1 (en) | Diagnostic in vitro method for assessing Von Willebrand Disease and bleeding risk associated with Von Willebrand Disease and acquired or congenital disorders of platelet function | |
Kovač et al. | Influence of DOACS and DOAC-REMOVE® on coagulation assays during thrombophilia testing in DOAC-treated patients | |
Flood et al. | von Willebrand disease: biological diagnosis | |
Time | Von Willebrand Disease Laboratory Workup | |
Hanif et al. | Evaluation of Pro-C global for identification of defects in protein C/S anticoagulant pathway | |
Ledford-Kraemer | Activated Partial Thromboplastin Time (APTT) Testing | |
Penn et al. | Comparison of the Siemens vWF: RCo and the Instrumentation Laboratory HaemosIL von Willebrand factor activity assays for the diagnosis of von Willebrand disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20181205 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190930 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190930 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20191226 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200302 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200331 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200730 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201026 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201216 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210113 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210323 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210401 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6864008 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |